We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

We'll first hear about a study that found a steep decline in non–small cell lung cancer mortality from 2013 to 2016. Then, we'll close out with a review of a report on the addition of locoregional radiotherapy to chemotherapy in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma.

Coverage of stories discussed this week on ascopost.com:

Study Suggests Drop in Non–Small Cell Lung Cancer Mortality Rates Due to Treatment Advances, Reduction in Incidence

Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma